TNBC

14 registered clinical trials studyying TNBC — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadj NCT07491822	Tianjin Medical University Cancer Institute and Hospital	N/A
Not Yet Recruiting	A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in NCT07441512	Hu Hai	Phase 2
Enrolling By Invitation	A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC NCT07376629	Huabo Biopharm Co., Ltd.	Phase 2
Recruiting	Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple NCT07017673	Cedars-Sinai Medical Center	Phase 2
Not Yet Recruiting	Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients NCT07021261	Fudan University	Phase 3
Recruiting	A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S NCT06682793	A2 Biotherapeutics Inc.	Phase 1 / Phase 2
Recruiting	HS-10502 Combination Treatment in Patients With Advanced Solid Tumors NCT06769425	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Phase 1
Recruiting	Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and B NCT06991790	Peking University Cancer Hospital & Institute	—
Not Yet Recruiting	A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 NCT06746870	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	Phase 2
Not Yet Recruiting	SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases NCT06210438	Fudan University	Phase 2
Recruiting	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combinat NCT05581004	Genentech, Inc.	Phase 1
Active Not Recruiting	A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC NCT05918133	Biotheus Inc.	Phase 1 / Phase 2
Recruiting	The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750	PMV Pharmaceuticals, Inc	Phase 1 / Phase 2
Available	An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Pa NCT07536815	CytoDyn, Inc.	—